Peer-reviewed article confirms that qualigen's fastpack® is as accurate in thyroid stimulating hormone measurement -- and much faster -- than a leading laboratory method

Carlsbad, calif., oct. 19, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, today announces the publication of a study in the peer-reviewed, open-source journal, diagnostics, validating the company's point of care fastpack® ip (“fastpack”) diagnostic test as comparable to an industry-leading laboratory method in determining thyroid stimulating hormone (tsh) levels in blood.
QLGN Ratings Summary
QLGN Quant Ranking